No Data
No Data
Nusano and PharmaLogic Announce Strategic Supply Agreement to Enable Current and Emerging Radiopharmaceuticals
VALENCIA, Calif. and BOCA RATON, Fla., July 10, 2024 /PRNewswire/ -- Nusano Inc. ("Nusano"), a physics company transforming the production of medical radioisotopes, and PharmaLogic Holdings Corp. ("
Abdera Therapeutics Announces FDA Fast Track Designation for ABD-147, a Next-Generation Precision Radiopharmaceutical Therapy, for the Treatment of Patients With Extensive-stage Small Cell Lung Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Abdera Therapeutics Inc., a biopharmaceutical company leveraging its advanced antibody engineering ROVEr platform to design and develop tunable, precision
Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?
H.C. Wainwright Maintains Actinium(ATNM.US) With Buy Rating, Maintains Target Price $50
H.C. Wainwright analyst Joseph Pantginis maintains $Actinium(ATNM.US)$ with a buy rating, and maintains the target price at $50.According to TipRanks data, the analyst has a success rate of 37.3% and
Express News | HC Wainwright & Co. Reiterates Buy on Actinium Pharma, Maintains $50 Price Target
Actinium Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/17/2024 515.76% HC Wainwright & Co. $50 → $50 Reiterates Buy → Buy 05/21/2024 515.76% HC Wainwright & C
No Data